The basis for determining Medicare payment rates for clinical diagnostic laboratory tests is changing. These changes will be important for all payers and providers to follow for future reimbursement and contract negotiations.
A chief medical officer for a major payer outlines the challenges making sure that certain high-cost therapies are directed to the patients who need them.
Medicare beneficiaries attributed to small practices in accountable care organizations (ACOs) achieve greater savings than beneficiaries attributed to large practices in ACOs.
Treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with FF/VI or UMEC/VI reduced exacerbation-related costs associated with chronic obstructive pulmonary disease (COPD) in the US healthcare system.
Substitutive Hospital at Home care for 4 common conditions is associated with cost savings.
Stereotactic body radiation therapy for low- to intermediate-risk prostate cancer has potential cost savings and may improve access to radiation, increase convenience, and boost quality of life.
Pilot testing of guidelines for the laboratory monitoring of high-risk medications shows that monitoring is highly variable and that there is room for improvement.
Small weight loss was reported by overweight/obese individuals targeted for telephonic wellness coaching in this large retrospective study using pre-post design.
Pneumococcal polysaccharide vaccination of healthcare workers during an influenza pandemic is cost-effective from a societal perspective but not from a hospital perspective without external subsidy.
Out-of-pocket payments differ widely among oral oncolytic options. As cost for therapy becomes a greater part of treatment decisions, an understanding of patient out-of-pocket cost will be critical in informing choices.
The actual costs of implementing the evidence-based Diabetes Prevention Program (DPP) were compared with the latest reimbursement rates provided by CMS.